Boston Scientific posts positive stroke prevention data for Watchman

Boston Scientific posts positive stroke prevention data for Watchman

The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and efficacy goals in the closely watched CHAMPION-AF study.

Data Highlights the WATCHMAN FLX Device

Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a broad population of patients with non-valvular atrial fibrillation (NVAF). Key results…